LCZ696 demonstrated superiority to enalapril in composite death from cardiovascular causes and hospitalization for heart failure.
Does LCZ696 reduce composite death from cardiovascular causes and hospitalization for HF compared to enalapril in patients with systolic heart failure having reduced ejection fractions?
This review highlights the superiority of the novel angiotensin-neprilysin inhibitor LCZ696 over enalapril in reducing cardiovascular death and heart failure hospitalizations in patients with HFrEF.
Angiotensin-converting enzyme inhibitors (ACEIs) have been the cornerstone in systolic heart failure (HF) regimens over the past 25 years. Their ability to block the renin-angiotensin-aldosterone system and their vasodilatory properties has repeatedly been shown to lower morbidity and mortality in patients with HF having reduced ejection fractions. In August 2014, the New England Journal of Medicine published a large trial studying a novel LCZ696 (angiotensin-neprilysin inhibition) agent against enalapril, an ACEI. In the phase III trial, LCZ696 demonstrated superiority to enalapril in composite death from cardiovascular causes and hospitalization for HF. The trial was stopped early due to overwhelming benefit of the study agent. This article provides an extensive review of the mechanism of action, pharmacokinetic properties, clinical efficacy, safety, and tolerability of LCZ696.
Pham et al. (Wed,) conducted a review in systolic heart failure with reduced ejection fraction. LCZ696 vs. enalapril was evaluated on composite death from cardiovascular causes and hospitalization for HF. LCZ696 demonstrated superiority to enalapril in composite death from cardiovascular causes and hospitalization for heart failure.